Northern Trust
TCRX icon

Northern Trust’s TScan Therapeutics TCRX Stock Holding History

Northern Trust’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
138,778
+41,330
+42% +$44K ﹤0.01% 4041
2026
Q1 		$98.4K Sell
97,448
-750
-0.8% -$801 ﹤0.01% 4112
2025
Q4 		$98.2K Sell
98,198
-350
-0.4% -$507 ﹤0.01% 4144
2025
Q3 		$179K Hold
98,548
– – ﹤0.01% 4013
2025
Q2 		$143K Sell
98,548
-231,476
-70% -$334K ﹤0.01% 4030
2025
Q1 		$455K Buy
330,024
+7,928
+2% +$17.1K ﹤0.01% 3610
2024
Q4 		$979K Sell
322,096
-2,180
-0.7% -$9.88K ﹤0.01% 3403
2024
Q3 		$1.61M Buy
324,276
+226,764
+233% +$1.37M ﹤0.01% 3125
2024
Q2 		$570K Buy
97,512
+20,552
+27% +$162K ﹤0.01% 3460
2024
Q1 		$611K Buy
76,960
+5,349
+7% +$33.6K ﹤0.01% 3494
2023
Q4 		$417K Sell
71,611
-365
-0.5% -$1.67K ﹤0.01% 3604
2023
Q3 		$184K Buy
71,976
+56,921
+378% +$133K ﹤0.01% 3844
2023
Q2 		$37.6K Buy
15,055
+905
+6% +$2.43K ﹤0.01% 4283
2023
Q1 		$29.7K Buy
14,150
+2,905
+26% +$6.9K ﹤0.01% 4375
2022
Q4 		$17.4K Buy
+11,245
New +$27.6K ﹤0.01% 4514

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Northern Trust's TCRX Position: Q2 2026 in Review

Northern Trust increased its TScan Therapeutics (TCRX) stake by 42% in Q2 2026, buying an estimated $44K and bringing the position to 138,778 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Northern Trust first reported a position in TCRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.61M in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Northern Trust held 138,778 shares of TScan Therapeutics worth $136K as of Q2 2026.
  • Northern Trust bought 41,330 TScan Therapeutics shares in Q2 2026, an estimated $44K.
  • TScan Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4041 holding.
  • Northern Trust first reported a position in TScan Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Northern Trust's TScan Therapeutics position peaked at $1.61M in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.